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Known risk factors for breast cancer do not account for a significant proportion of the overall incidence. Reproductive factors and endogenous
hormones are thought to be responsible for a large component of risk. An environmental contribution has been sought in the past to explain the
international trends in breast cancer rates and changes in risk among migrating populations. Recently, environmental research has turned to
investigation of exogenous chemical exposures, including environmental contamination, as potential risk factors that may arise from the hormonal
activity or from the carcinogenicity of many of these chemicals. Several reports since 1991 suggest that organochlorines may be a risk factor for
breast cancer. The data are strongest for DDT. For PCBs, the results to date have been equivocal if not entirely negative. However, different groups
of polychlorinated biphenyl (PCB) congeners are known to provoke biological responses that are structure specific. A wide divergence of estrogenic
response, cytochrome P450 activity, and biological half-life exists within these groups of PCB congeners. Therefore, understanding breast-cancer
risk from PCB exposure requires attention to congener structures in complex mixtures and to temporal changes in exposure. Investigation of
environmental contributions to breast cancer risk offers the potential for understanding more about the etiology of this complex disease and may
also provide opportunities for prevention of the most common cancer among women in the United States. - Environ Health Perspect
103(Suppl 7):141-145 (1995)
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Introduction
Reproductive history and hormonal factors
are widely accepted as major risk factors for
breast cancer. Environmental exposures
may also be important in breast cancer eti-
ology, as indicated by international varia-
tions in incidence and studies of migrant
populations. However, research on specific
environmental chemicals that may con-
tribute to breast cancer risk is in its infancy.
Recently, preliminary data have emerged
suggesting that breast cancer risk may be
associated with exposure to persistent
organochlorines. This class of chemicals
includes DDT, chlordane, polychlorinated
biphenyls, hexachlorocyclohexane, kepone,
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and polybrominated biphenyls. These
chemicals are carcinogenic in animals and
are sequestered in fatty tissues. Their lipid
solubility, low volatility, and chemical
inertness lead to their residence in the body
for alifetime.
Interest in the relationship of these
chemicals to breast cancer arose because, in
addition to their persistence and carcino-
genicity, certain ofthese chemicals are able
to mimic the activity of reproductive hor-
mones in laboratory tests and in wildlife.
In addition, one research group made two
observations among women that suggested
a hormonal effect of DDT; Rogan and
colleagues at the National Institute of
Environmental Health Sciences (NIEHS)
(1) reported that women with higher levels
of DDE reported shorter durations of lac-
tation. DDE is the major residue of DDT
in the environment, and it is usually found
in humans at higher levels and more




Four recent case-control studies have
linked environmental organochlorine expo-
sures to breast cancer risk (Table 1). A fifth
study reported no statistically significant
differences in DDE between cases and
controls, although the results for the
African-American and Caucasian sub-
groups were consistent with previous stud-
ies. The relative risks reported in these
studies are in the range of 2 to 10, so that
they rank among the higher risks observed
for breast cancer in the epidemiologic liter-
ature. The evidence is strongest in support-
ing a relationship between DDT and breast
cancer. An earlier study while not disprov-
ing this hypothesis failed to find an associa-
tion (2). Apart from DDT, the data for
other organochlorines have not shown any
consistent associations, but polychlorinated
biphenyls (PCBs) and hexachlorocyclo-
hexane ([HCH] or benzene hexachloride
[BHC]) were significantly elevated in
two studies.
The first was the studyby Frank Falck et
al. (3), showing approximately 50% higher
levels of DDE, DDT, and higher chlori-
nated PCBs among 20 breast cancer cases,
compared with 20 controls. No significant
differences were found for hexachloroben-
zene (HCB) or chlordane residues. HCH
was not detected. The risk for DDT
although elevated, was not statistically sig-
nificant. There was approximately 1%
increased risk for every 10 ppb ofDDE and
PCBs in adipose tissue. While a striking
association was observed in this study, its
import is limited by the pilot nature ofthe
design, which did not allow adjustment for
potential confounding reproductive factors.
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Table 1. Case-control studies of breast cancer and DDT exposure.
Cases Controls
Davies, 1974(26) 29 29
Wassermann et al., 1976 (27) 9 5 Tumor>normal mammarytissue
Albert et al., 1982 (28) 8 7 Tumor>normal mammarytissue
Unger etal., 1984 (2) 14 21
18 35
Mussalo-Rauhamaa et al., 1990 (5) 44 33 *
Falck et al., 1992 (3) 20 20 -3 (67th>33rd percentile)
Wolff et al., 1993 (4) 58 171 -4(lOth-9Oth percentile)
Dewailly et al., 1994(6) 18 17 ER+: 9 (67th>33rd percentile)
Kriegeretal., 1994(7) 150 150
*Relative risk of -10 seen for women whose BHC (HCH, hexachlorocyclohexane) levels were above 0.1 ppm in
adipose. **Adjusted trends showed risks of 2 to 4 (not statistically significant ) in the upper terciles of black and
white women (50 cases and controls in each group).
The second study was part of the the
New York University Medical Center
Women's Health Study cohort (4). Blood
serum specimens from 58 breast cancer
cases, collected 1 to 6 months before diag-
nosis, and 171 individually matched
controls from the same cohort were avail-
able. As with the Falck study, levels of
DDE were significantly higher among
breast cancer cases than among controls.
PCB levels were also higher among cases,
but the differences were not statistically
significant. Women in the upper decile of
serum DDE had about 4-fold increased
risk compared with those having the lowest
concentrations. There was approximately
9% increased risk for every 1 ppb ofDDE
in blood serum. Since the usual concentra-
tion of chemicals in adipose tissue is
approximately 200 times that in blood
serum, these data were comparable to the
findings in the Falckstudy (3).
Similar risks for breast cancer were
found among Finnish women with ele-
vated levels ofP-hexachlorocyclohexane, a
lindane-derived residue (5). A recent
report from Canada found significantly
higher levels ofDDE in estrogen receptor-
positive breast cancer cases compared with
controls (6).
A fifth study used blood serum that had
been gathered during the late 1960s in a
California health maintenance organization
1 to 20 years before cancer diagnosis (7).
Levels ofserum organochlorines were com-
pared among 150 breast cancer cases (one-
third each Caucasian, African-American,
andAsian) and an equal number ofcontrols
from the same cohort. Although there were
no differences in DDE and PCB levels
when the three groups were considered in
the aggregate, serum DDE levels appeared
to be as important a risk factor among
African-American and Caucasian women
(but not among Asians) as in previous
studies (Table 2).
In summary, the current status of the
case-control studies relating breast cancer
risk to organochlorine exposure suggests a
relationship with DDT exposure (Tables 1,
2). The magnitude of the estimated risks
from the recently cited studies is similar to
the risks that have been estimated using
data from experimental animals (8,9).
PCBs and Breast Cancer Risk
The evidence for risk from exposure to
PCBs and other organochlorines is equivo-
cal, but there are interesting trends in the
available data for PCBs that merit further
study. Since PCBs occur as complex mix-
tures, their biological effects might be
expected to represent an integrated response
to the individual components ofthese mix-
tures. However, all but one of the cited
reports have used total PCBs as the exposure
measure. Total PCBs as found in humans
can represent the sum of 10 to 40 PCB con-
geners, depending on the laboratory method
and on an individual's exposure.
An alternative approach is to investigate
the PCB exposures in a congener-specific
fashion, which may reveal structure-activ-
ity relationships like those observed in
experimental animals. A first important
example is the potential for a range of
estrogenic and antiestrogenic activity for
congeners with specific chlorine substitu-
tion patterns (Figure 1)(10). Second, per-
sistence, or resistance to metabolism, is also
stereospecific. A third inherent PCB prop-
erty, the potential for inducing cytochrome
P450 enzymes, also varies according to
structure (Table 3). Three possible struc-
ture-activity groups (I, II, III) can be
established that categorize these properties.
Their currently recognized estrogenic
response may be characterized as estro-
genic, antiestrogenic, and neither (groups
I-III; Figure 1, Table 3). It is apparent that
the estrogenic PCB congeners (group I) are
characterized by a chlorine pattern that is
also known to be more rapidly metabolized
than the coplanar or typical persistent con-
geners (Table 3)(11). Group I congeners
have two adjacent nonsubstituted lateral
carbon atoms on at least one ofthebiphenyl
Table 2. Relative risks forterciles of DDE exposure in studies of breast cancer.
DDE levels, ng/ml <1 <5 <10 <15 <20 <25 <30 <35 .40
Krieger etal., 1994(7)
Whites, DDE tercile mean 14 31 72 ppb
OR (n) p=0.24 1.0 1.8 2.4
Blacks, DDEtercile mean 23 44 102 ppb
OR (n=100) p=0.07 1.0 2.0 3.8
Asians, DDE tercile mean 20 43 89 ppb
OR (n=100) p=0.52 1.0 0.9 0.7
Falck etal., 1992 (3)
Whites, estimated DDE tercile 2.3 7.6 13 ppb
OR (n=40) 1.0 3.6 13.3
Wolff et al., 1993 (4)
Whites, estimated DDEtercile 1.0 8.5 16 ppb
OR (n=229) 1.0 1.9 3.5
Dewailly et al., 1994(6)
Whites, estimated DDE tercile 1.2 3.8 6.5 ppb
OR (n=35) 1.0 3.0 8.9
Abbreviation: OR, odds ratio. Regression coefficient, b, was used to estimate OR for Wolff, b=0.0823; Falck,
b=0.00122; and Dewailly, b=0.00207 (ER+ only, n=9), applied to DDE levels among 17 controls. These coeffi-
cients were statistically significant. Wolff, Falck, and Dewailly data for terciles were computed from mean ±1 SD,
and ORs were computed from the stipulated logistic regression coefficients. The Falck and Dewailly data were
given for adipose concentrations that have been converted to approximate serum concentrations by dividing by
200. The Falck adipose terciles were 466, 1526, 2585 ng/g for pooled means ±1 SD of cases and controls. The
Dewaillyterciles were 238, 765, and 1292 ng/g forcontrols.








para Substitution, >5 chlorines,
persistent, P450 induction
Figure 1. Structure-activity relationships for PCB con-
geners (para-, 4-; meta-, 3- or 5-; ortho-, 2- or6-).
rings by definition, including one or two
unsubstituted 4 or para positions. PCBs
with this structure, including the Aroclor
1221 mixture that contains numerous con-
geners from this group, have estrogenic
activity, as documented by their ability to
increase uterine weight and cause preco-
cious puberty (12), to bind to the estrogen
receptor (13), and to enhance proliferation
ofMCF-7 breast tumor cells (14).
Group II PCBs have 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD)- or
dioxinlike properties that have been shown
to be antiestrogenic. Their antiestrogenicity
is thought to arise from interaction with the
Ah receptor. This receptor best fits con-
geners that can achieve coplanar stereo-
chemistry of the biphenyl rings (10). The
structural requirement for coplanarity is the
absence of2, 6, or orthochlorines. The most
active congeners are substituted at the
3,4 positions on both biphenyl rings. As a
result, these non-orthosubstituted congeners
have no chlorines on the 2 (or the equiva-
lent 6) positions, providing an avenue for
metabolism at these adjacent unsubstituted
carbon atoms, albeit not as facile as for
group I. Therefore, the coplanar PCBs may
be more persistent than group I and yet
more readily metabolized than the very per-
sistent congeners in group III. Also, some
PCBs with a single ortho chlorine appear to
retain some of the characteristics of group
II. For example, the mono-ortho PCB
2,3',4,4',5,5'-hexaCB is approximately a
100-fold less active than the non-ortho
analog 3,3',4,4',5-pentaCB (10).
The antiestrogenic effects of the PCB
congeners in group II could lead to protec-
tion against breast cancer and could coun-
teract the estrogenic activity of other PCB
congeners. TCDD administration to rats
caused a decrease in normally occurring
breast and uterine tumors and in chemi-
cally induced mammary tumors (15,16).
TCDD and structural analogs including
the coplanar PCBs are antiestrogenic in the
MCF-7 breast cancer line (10). Mixtures
exhibit properties consistent with their
multiple components. Thus, while the
estrogenic PCB mixture Aroclor 1221
causes precocious puberty (12), another
mixture (Clophen A-50, which contains
many antiestrogenic congeners) delays
onset of puberty in female rats(17).
Similarly estrogenic organochlorines sup-
port implantation and pregnancy, while
TCDD inhibits implantation (18).
Group III congeners are highly substi-
tuted, persistent PCBs. Some ofthese con-
geners may have weak estrogenic activity
(19). Moreover, their extensive chlorina-
tion means that both 2 and 4 positions are
substituted in many congeners and that
there are few ifany adjacent unsubstituted
carbons. These configurations are not
amenable to metabolism, and therefore
these PCBs are very persistent in the body.
In addition to the diverse estrogenicity
and metabolic rate of these three groups,
the ability to induce cytochrome P450
Table 3. Potential PCB biological activity according to congener structure.
Persistence,
Isomers Activation half-life Effect
Low chlorination Hydroxylation -(months) Estrogenicity
0 to 1 orthochlorine, Ah receptor, CYPlA, ±(1-5years) Antiestrogen, EGFR, metabolism of
coplanar (CYP2A) carcinogens and estradiol (to 2-hydroxy)
>1 orthochlorine CYP2B, (CYP2A, lAl) ++ (>10years) Metabolism ofcarcinogens and
estradiol (to 16a-hydroxy)
isozymes also varies according to chlorine
substitution pattern. Group II congeners
induce the CYPIA family through their
binding with the Ah receptor, an effect
that is similar to induction by 3-methyl-
cholanthrene or TCDD. Group III shows
activity more like that of phenobarbital,
inducing the CYP2B family ofcytochrome
P450 enzymes. There is some overlap in
the ability of PCB congeners to induce
enzyme activity, so that group III may
induce the CYPlAl group to some extent
and CYP2A1 may be induced by both
groups II and III (20).
From Table 3, it can be seen that
marked differences in persistence of PCB
congener types also limit the period oftime
following exposure during which a biologi-
cal effect could take place. Group I's estro-
genic activity would be available for.only a
few months before elimination was com-
plete in humans. The antiestrogenic effects
ofthe coplanar PCBs in group II may pre-
vail longer than group I, but such activity
may exist over a shorter time period than
the effects ofother, noncoplanar congeners
in group III. From this line of reasoning,
the risk for breast cancer from exposure to
group II could be hypothesized to be lower
in the short term (e.g., protective effect of
antiestrogenic exposures) and higher in the
long term (e.g., persistent exposures to a
carcinogen and to an inducer of carcino-
gen-metabolizing enzymes). It has also
been postulated that group II compounds
are protective by facilitating metabolism of
estradiol to a less genotoxic estrone, the 2-
hydroxy isomer (21). Group III, on the
other hand, may affect cancer over the long
term by influencing estradiol metabolism to
the more toxic 16a-hydroxy isomer and by
enhancing metabolism of carcinogens. In
addition, some congeners in this category
mayalso act as hormonal agonists (19).
In summary, both the hormonal activ-
ity and the metabolic profile of persistent
organochlorines must be taken into
account in assessment of their long-term
effects. The evidence to support this con-
cept comes mainly from experimental data
such as that cited above. Human data are
limited. There is no evidence for an associ-
ation of PCBs with breast cancer from the
few reported mortality studies (22).
However, the exposure measures in these
reports relied only on duration ofexposure,
not on any personal or biological measures
or on any information on PCB congeners.
Also these studies were based on mortality,
rather than incidence, data. Very limited
data from studies ofdioxin-exposed groups
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Table 4. Breast cancer incidence (CI) and mortality studies in populations exposed to TCDD.
Breast cancer Exposure Relative risk
Bertazzi et al. (29) Seveso
1 case Zone 1-most exposed 0.5
10 cases Zone 2-less exposed 0.7
106 cases Zone R-little exposure 1.1
Manz et al. (30) 9 deaths Manufacture ofTCP, 2,4,5-T 2.15
Flesch-Janys et al. (31) 10 deaths Manufacture of HCH, phenoxys 2.37
Cl 1.3-4.0
suggest that short-term exposures to
TCDD may show a protective effect (e.g.,
in Seveso), while long-term exposures to
TCDD and other organochlorines in man-
ufacture show slightly elevated risk (Table
4). Further studies, taking into account the
complex qualitative nature of toxicity
including the stereospecificity and toxico-
kinetics of organochlorines, should be
undertaken to examine the health risks of
such exposures.
Conclusions
Several mechanisms, not necessarily mutu-
ally exclusive, can be proposed to explain
the association between organochlorine
exposure and breast cancer risk. First, since
they mimic estrogens in experimental stud-
ies, organochlorines may serve as cancer
promoters in the same fashion as steroid
hormones do. That is, estrogen promotes
tumorigenesis in animal experiments, and
epidemiologic evidence supports a similar
mechanism in humans. In vitro experi-
ments demonstrate the ability of estrogen
and its synthetic analogs to cause prolifera-
tion of breast cancer cells in culture
(14,23). Moreover, estrogenic chemicals
modulate the expression of certain onco-
genes, and their potential estrogenic char-
acter may dispose organochlorines to be
cancer promoters through this mechanism.
Second, a cogent model can be devel-
oped around the ability of these chemicals
to induce cytochrome P450 enzymes.
These enzymes bioactivate many chemical
carcinogens such as polycyclic aromatic
hydrocarbons (PAH), the prototypical
animal model for chemical carcinogenesis,
including breast cancer. P450 also metabo-
lizes estrogen, which can lead to genotoxic
DNA adducts. Finally, a possible nonbio-
logical explanation for these associations
may be that persistent organochlorines act
as a surrogate measure for carcinogenic
dietary factors or other early exposure to
carcinogens that have not yet been identi-
fied in epidemiologic studies.
DDT and PCB levels in the U. S. pop-
ulation are gradually receding, thanks to
the success of regulatory action in the
1970s (24). Ifthe studies linking organo-
chlorines to breast cancer hold true, then
the number of affected women may be
limited to those with exposures during
1950 to 1972. However, DDT is still
widely used in developing countries where
it may affect public health or cross inter-
national borders. Other environmental
exposures deserve attention for their
potential influence on breast cancer. There
are myriad other potentially estrogenic
chemicals in commerce that we are not
able to detect long after exposure, such as
atrazine and methoxychlor (25). Another
prime candidate for breast cancer initia-
tion is the family of PAHs, which are
rapidly metabolized and cannot be traced
long after exposure. The reported greater
risk of breast cancer among women who
began smoking at an early age suggests
that we should study environmental expo-
sures to this class ofchemicals early in life.
Unfortunately it will be difficult to obtain
adequate dose-metrics for such chemical
exposures into epidemiological studies.
Nevertheless, in spite of the difficulties
in exposure assessment and whether breast
cancer risk from organochlorines holds up
to further scrutiny, we should actively seek
out other possible chemical carcinogens in
the environment, current or past, that
could also be involved in breast cancer risk.
In addition, in both animal research and
human epidemiological studies, we should
seek to identify biological mechanisms to
explain how such risk maycome about.
Rates ofbreast cancer occurrence in the
United States have steadily risen since
1940. During that same period, levels of
pesticide and PCB residues in human adi-
pose tissue in the United States have
shown parallel increase, following their
introduction into commerce around the
time ofWorld War II. Since then, despite
much research on the question, only three
factors have been generally agreed to be
strongly linked to breast cancer: age, coun-
try ofbirth, and family history. These fac-
tors are not readily amenable to change.
Medicine has done its job well in finding
new avenues of treatment and detection,
and hence the mortality rates have been sta-
ble over the recent past. However, the exis-
tence of a cure without a cause continues
because no pathways for prevention have
been found. We hope that our research may
be a step in the direction of prevention as
well as to better understanding the cause of
breast cancer.
Three recent publications provide fur-
ther relevant information. In describing a
new analytic method, Djordjevic et al. (32)
observed higher levels of several pesticides
including DDT, as well as PCBs, among 5
cases compared with 5 controls (difference
not statistically significant). Gladen and
Rogan (33) confirmed the negative impact
of DDE on duration oflactation in a sec-
ond group of women from Mexico.
Finally, p,p'-DDE demonstrated antian-
drogenic responses both in vitro and in
vivo in the rat (34), observations that
underscore the importance ofinvestigating
a range of hormone function for environ-
mental contaminants (35).
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